European Specialization in Oncology Pharmacy (EUSOP)
The European Society of Oncology Pharmacy (ESOP) is proud to be able to announce the first European Certification Program for Oncology Pharmacy (EUSOP) provided by the Academy of the European Society of Oncology Pharmacy.
The 100 hours program consists webinars, an international workshop (Excellence Course for Oncology Pharmacy – ExCOP) and national trainings.
After passing the whole EUSOP program, the title “European Pharmacist in Oncology Pharmacy” will be conferred.
If you have already attended oncology trainings in your own country, there is a possibility of acceptance within the 100 hours which will be checked and approved by the ESOP accreditation committee. This means you might not have to attend the full EUSOP program. After registration a personal Score Card we be send out where former attended courses can be stated.
The full program with a total of 100 hours contains:
- Basics of Oncology Pharmacy (18 hours)
- Oncology Pharmacy in practice (11 hours)
- Clinical Oncology Pharmacy (46 hours)
- Biologics in Oncology Pharmacy (25 hours)
The Program divides in 50 hours of e-learning, 12 hours of National Training and 38 hours of International Training (ExCOP - Excellence Course for Oncology Pharmacy).
Education content Download (pdf)»
Curriculum Download (pdf) »
EUSOP registration form Download (pdf)»
Excellence Course for Oncology Pharmacy – ExCOP 2019
The first International Workshop - ExCOP - took place from June 24th – 28th, 2019 in Hamburg, Germany.
Sponsors 1st ExCOP 2019
||Berner International GmbH
||CODAN pvb Medical GmbH
||ICU Medical BV
||B. Braun Melsungen AG
Amount: 1.500 EUR
||Equashield/ Maco Pharma International GmbH
Further Information regarding Curriculum Part 4 „Biologics in Oncology Pharmacy“
ESOP certified education about biosimilars
Genetically engineered products were first introduced in 1982 with insulin. Since 2006, imitation products, so-called biosimilars, entered the pharmaceutical market. Biosimilars emerged in the past years with the expiration of the patent period of these drugs. Biosimilars are large, complex molecules that are similar but not identical to their classical pharmaceutical equivalents. Their preparation is laborious and costly, and barriers must be overcome for their approval. Immunogenicity issues are also associated with the use of biosimilars. The safety of biosimilars needs to be carefully and constantly monitored. Nonetheless, biosimilars are a critical element in the cost-effective use of biopharmaceuticals with a benefit both for patients and the healthcare system.
To meet up with today's needs on biosimilars, ESOP has developed a training program on biosimilars. The program includes information on biosimilars, current guidelines and recommended handling procedures for biosimilars.
Delivery of this program is based on: webinars by professionals in the field; regional lectures at scientific conferences in each participating country; and case discussions. A certificate will be given on completion of the training program.
- Explain the importance of analytical work in the development of biosimilars and regulatory approvals.
- Descriptions of the concepts of extrapolation of immunogenicity and indications based on the integrity of the evidence
- To assess the importance of access to pharmacoeconomic and biosimilars in oncology in Europe.
- Summarise the current and emerging data on oncology monoclonal antibody biosimilars and their potential to provide optimal combination therapy.
The goal of the ESOP certified program on biosimilars is to spread knowledge on the meaningful use of biosimilars. The program can be delivered in the national language of the country being given whilst still retaining the same content.
This training is aimed at oncology pharmacists interested in advancing their practice on treatment of cancer using biosimilars.
The training is based on 3 pillars:
1. Knowledge transfer through specialist lectures on the Internet completed with knowledge examinations (webinars).
Regional lectures at scientific conferences in each participating country
3. Finally, personal work meetings for the discussion of patient cases and personal exchange with certificate.